Biocardia (BCDA) news
Recent news
BioCardia announces FDA confirms Helix transendocardial delivery catheter meeting minutes supporting follow-on de novo pre-submission for approval
AInvest Wire · 7d agoBioCardia - net proceeds expected to extend cash runway into Q1 2027
AInvest Wire · Jun 8, 2026BioCardia announces $4.4 million financing
AInvest Wire · Jun 8, 2026ImportantBioCardia more than double premarket after FDA approves medical instrument morth dna steerable introducer
BioCardia more than double premarket after FDA approves medical instrument morth dna steerable introducer The US Food and Drug Administration (FDA) recently approved BioCardia, Inc.'s (Nasdaq: BCDA) Morph DNA Steerable Introducer Sheath product family [1]. This development is a significant step…
AInvest Wire · Aug 29, 2024Biocardia: FDA OKs CardiAMP heart failure II protocol amendment
Biocardia: FDA OKs CardiAMP heart failure II protocol amendment The Food and Drug Administration (FDA) has granted Biocardia, Inc., a prominent developer of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, approval for its proposed CardiAMP Heart Failure II study…
AInvest Wire · Aug 21, 2024Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.